Part VIII Entering Information Into the Urology Report Form

Size: px
Start display at page:

Download "Part VIII Entering Information Into the Urology Report Form"

Transcription

1 North Carolina Central Cancer Registry Instructions and Reporting Requirements Module 8 Electronic Reporting For Urology Physician Practices May 2013 North Carolina Central Cancer Registry State Center for Health Statistics Division of Public Health Department of Health and Human Services 1908 Mail Service Center Raleigh, NC

2 Part VIII Entering Information Into

3 Before beginning a new report, read the following VERY IMPORTANT information A separate report must be completed and submitted for each independent primary tumor. o Example: If a patient is diagnosed with bladder cancer and a separate kidney cancer, a separate report must be submitted for each diagnosis. o Please complete the urology reporting form as ACCURATELY and COMPLETELY as possible. o Once the report is free of errors and is successfully submitted, it is considered as having been reported to the NCCCR.

4 Before opening a new reporting form and beginning data entry: o Make sure all information necessary for entering the case is available and on hand o Review the chart in its entirety o Make notes on a note pad or scrap paper if necessary to facilitate data entry o Confirm any information that is confusing or unclear with the physician. Session times out after 30 minutes if no activity takes place. o All information entered for the case (and not submitted) will be lost. o All information necessary for completing the case should be on hand prior to beginning data entry for that case.

5 There is no Save functionality o Users must be able to complete data entry for the current case during the active session. o Cases are not saved until the case is completely entered, one of the Submit options is selected, and all error messages are cleared. o If it is known that more information is needed or will be forthcoming, hold the case for a later time. Do not start data entry. o Cases started, but not completed, cannot be accessed at a later time. o Any information will be lost and must be re-entered when the complete information is available.

6 Treatment information is very important: o Wait to enter report AFTER treatment plan is established Make sure START DATES for each treatment modality are known o It is not required for all treatment to be completed Treatment may continue for months or years o For patients who refuse treatment, do not receive treatment for any reason or when there is a decision not to treat (watchful waiting or active surveillance) Specifically record that decision of why there was not treatment in the treatment text area.

7 Text is CRITICAL! o Over 100 additional data items will be coded by the NCCCR staff after the report is submitted. o This coding is highly dependent on the text you provide. o Provide as much information and detail as possible to describe the case. o It is critical to the accuracy and completeness of the final coding for the reported case.

8 Screen Shots o A screen shot for each tab is provided in the following slides Each screen shot shows an example of what a completed screen would look like using a hypothetical prostate case o A table per screen shot is included with information on Each data field on the tab Any additional coding instructions for each tab o Pay particular attention to the format and content of the text areas used to describe the case A red asterisk [*] indicates a required field Text boxes allow a limited number of characters o Hover over the box with the mouse pointer to display information about the maximum number of characters allowed

9 Section VIII.1: Entering Patient Personal Data on the Demographic Tab

10 Section VIII.1: Entering Patient Personal Data on the Demographic Tab - continued Last Name* First Name* Middle Suffix Medical Rec # SSN* Special characters (,. / : # & *) are not allowed in name fields. Enter the name without special characters. For example, enter OHARA for O Hara. Letters, numbers and periods only are allowed. Letters, numbers and hyphens only are allowed. The SSN can be entered with or without hyphens. Unknown should be avoided is only allowed if the patient refused to provide their SSN. Sex/Gender* Insurance Birth Date* Place of Birth Race* Spanish Origin Vital Status Unknown should be avoided. Date of birth may not be blank or unknown. Code 999 (unknown) if not specifically stated. Do not assume patient was born in the U.S. Unknown should be avoided if at all possible. Race is very important in demographic studies. Request that this be dictated by the physician if not requested from the patient on the pre-visit paperwork. If patient is multiracial and one race is white, code the other race. Persons of Spanish or Hispanic origin may be of any race. If the patient is of Spanish or Hispanic origin, select the code that describes the specific origin. Use Code 0 (Non-Spanish) if there is no indication that patient is of Spanish/Hispanic Origin. Use Code 6 (Spanish/Hispanic NOS) if there is evidence (other than surname or maiden name) that the person is Hispanic, but cannot be assigned to the category in codes 1 5. Use Code 7 (Spanish Surname) when it is unknown if the patient is of Spanish/Hispanic Origin but the patient has a Spanish/Hispanic Surname. The Vital Status should remain Alive unless there is documentation of the patient s death prior to reporting the case.

11 Section VIII.1: Entering Patient Personal Data on the Demographic Tab - continued Date of Death If Date of Death is entered, it must be the latest date entered in the record. Date of Death Flag If Vital Status is Alive, leave the default flag of 11. If Vital Status is Dead, set the flag to12 ONLY if exact date is not known. If the date of death is known, this flag should be left blank. Refer to Section VII.2: General Instructions for Using the Data Entry Screens for more information on how to complete the Date and Date Flag fields. Industry and Occupation Date first seen with Cancer Date of Last Appt. Record the occupation and industry where the patient worked for the majority of their lifetime. Example: Industry: Education, Occupation: Teacher If the usual occupation is not clear, enter the current occupation. If no information is known about the patient s occupation, leave blank. Do not record Unknown. If the patient is a minor, or a student, or has never held an occupation (such as a homemaker), record Minor, Student or Never Worked. This is the first date the patient was seen at your office with a diagnosis of cancer. If the patient is diagnosed as a result of testing performed during the office visit, the date will be the date of this visit. This should not be blank or unknown. This is the last date the patient was seen at your office, regardless of the reason for the visit or the disease status. This should not be blank or unknown.

12 Section VIII.2: Entering Diagnostic Data on the Dx/Staging Tab Cannot be unknown. Estimate as closely as possible. Check this box ONLY WHEN the next case to be entered will be for the SAME patient. Each procedure must include: Date, Procedure, Place, Findings. Don t forget Age, Sex and Race. Use any available text field to provide additional pertinent information. Pathology information is very important. Be very detailed.

13 Section VIII.2: Entering Diagnostic Data on the Dx/Staging Tab - continued Keep Patient Address check box Check this box ONLY WHEN the next case to be entered will be for a DIFFERENT primary cancer for the SAME patient. For example, the patient has a bladder primary cancer and a separate kidney primary cancer to be reported. Important: This can be a real time saver but MUST be cleared when the next case will be for a different patient. Date of Dx* Place of Dx Enter the first date it was stated the patient had this cancer. This may be a physician s statement of diagnosis or it may be based on the results of a diagnostic test or procedure. Date of Diagnosis cannot be blank or unknown and must be the earliest of all dates except for Birth Date. Estimate as closely as possible if an exact date is unknown. At least a valid year must be recorded. If there is absolutely no information to even estimate the year, record the same year as the patient s first visit to your office. Refer to Section VII.2: General Instructions for Using the Data Entry Screens for more information on how to complete the Date and Date Flag fields. Enter the facility, treatment center, or physician s office that performed the first test or made the first statement that confirmed this diagnosis. If this was at your office, then enter your office name. If this is unknown, then record UNKNOWN.

14 Section VIII.2: Entering Diagnostic Data on the Dx/Staging Tab - continued Record the primary residence for the patient at the time of diagnosis. The address should be fully spelled out with standardized use of abbreviations and punctuation per U.S. Postal Service postal addressing standards. This is not necessarily the same as the patient s current address. If it is known that the patient was living at a different address at the time of diagnosis, enter as much as is known and record UNKNOWN in the remaining address fields. For example, if all that is known is the city, then enter the city, state and zip and enter UNKNOWN in the street address. If no information regarding the address at diagnosis is known, then enter the current address. This is preferred over recording the address as entirely unknown. Patient Address at Diagnosis City* Should be the street address. PO Box is allowed but should only be used if the physical address is not known. State* Zip* County* If the last four digits of the zip code are known, enter them preceded by a hyphen. Use the drop down menu to make a selection. Type the county name to begin the search. Special Codes: 998 Residence not in North Carolina. The address at diagnosis was a state other than North Carolina County is unknown. This is only allowed if the city is unknown.

15 Section VIII.2: Entering Diagnostic Data on the Dx/Staging Tab - continued Use free text in the following designated text areas to describe the results/findings of any diagnostic workup, staging workup, biopsies, and surgical procedures performed. For each procedure, record the date of the procedure, the procedure name, the place where the procedure took place, and the pertinent results/findings of the procedure. This should include pertinent negative findings in addition to positive findings. Example: 10/19/2011, CT ABD/PELVIS, UROL ASSOC. ENLARGED PROSTATE. NO ADENOPATHY. NO MET DZ SEEN Physical Exam Include age, rage and sex of patient Include pertinent information from the H&P including the evaluation of the location and extent of the tumor and other symptoms that may suggest further disease spread. X-rays Include the results of any imaging tests performed to evaluate the tumor Scopes This includes endoscopies, ultra-sounds, etc. Lab Values In addition to the lab test and result, state whether the test was considered to be elevated, abnormal or within normal limits Only lab tests that are diagnostic or prognostic for that primary site need to be summarized. Examples include CA-125, CEA, PSA, etc. Routine blood tests such as CBC do not need to be included

16 Section VIII.2: Entering Diagnostic Data on the Dx/Staging Tab - continued Use free text in the following designated text areas to describe the results/findings of any diagnostic workup, staging workup, biopsies, and surgical procedures performed. For each procedure, record the date of the procedure, the procedure name, the place where the procedure took place, and the pertinent results/findings of the procedure. This should include pertinent negative findings in addition to positive findings. Example: 10/19/2011, CT ABD/PELVIS, UROL ASSOC. ENLARGED PROSTATE. NO ADENOPATHY. NO MET DZ SEEN Path/Autopsy* This section is very important. Include the findings from all cytologic (FNA, brushings, etc.) and histologic (biopsy, surgical resection, etc.) examinations performed. Clearly separate each procedure and findings with separate statements. In addition to the basic text elements such as date, procedure, place and findings, include the status of the following: Final diagnosis as written on the report Location of the tumor (primary site and laterality) Histology (EXACTLY as stated on the report) Behavior (invasive or in situ) Grade including site specific grade such as Gleason Tumor Size Tumor extension into other surrounding tissues Surgical Margins # Lymph Nodes removed and positive Examination of metastatic tissues Ancillary studies such as tumor markers Relevant findings from the gross examination including aids in identifying the primary site and extent of disease

17 Section VIII.3: Entering Facility Data on the Hospital Tab

18 Section VIII.3: Entering Facility Data on the Hospital Tab - continued Facility information must be entered by the user each time the user logs on to the Eureka system, Facility information only needs to be entered for first case entered. Both Submit buttons will retain the facility information for subsequent cases entered during this active session. Facility Name* Address 1* and Address 2 City* State* Zip* County* Facility #* Enter the official name of the facility you are reporting cases for. Post Office Box addresses are not accepted for Facility address. Use the drop down menu to make a selection. Type the county name to begin the search. Unknown is not allowed. Select the Facility Identification Number assigned to the physician office in which you are reporting cases. This was the number assigned to your office when you requested a Eureka account.

19 Section VIII.3: Entering Facility Data on the Hospital Tab - continued If the patient was seen at another hospital, treatment center or physician s office for the management of this tumor, select the appropriate code for Referred From or Referred To from the drop down menu. If the facility or physician s office for the Referred From of Referred To fields was not an available option in the associated selection boxes, leave the default o and record the name of the facility in the Remarks text section. There are several special codes for when the exact facility name is not known or the patient was referred out of state. Search the menu options carefully before making a final selection. Referred From Referred To Attending MD Surgeon NPI Numbers Patient seen elsewhere for management of this tumor before visit at your office. If the patient was not referred, leave the default of Patient seen elsewhere for the management of this tumor after visit at your office. If the patient was not referred, leave the default of Enter the name of the physician at your office caring for the patient. Enter the name of the physician who performed the cancer-directed surgery for the treatment of this tumor. For each facility and physician recorded above, enter their NPI number assigned by CMS. This must be entered as a 10-digit number. To obtain NPI numbers for your office and other local providers start with the billing department. It may be helpful to create a list of numbers for physicians and hospitals commonly participating in the care of your patients to have on hand when entering cases. For NPI numbers not available by the billing department, use the Centers for Medicare and Medicaid Services (CMS) website. The Data Dissemination page provides further links to access a searchable database where you can search for individual providers. NPI Registry (searchable data base): Click on Data Dissemination

20 Section VIII.4: Entering Tumor Data on the Tumor Data Tab Must be recorded in MM. Convert CM to MM. If the patient did not receive that particular type of treatment, select the flag code of 11. Each procedure must include: Date, Procedure Name and Place (where the procedure was done). Findings, if summarized on the previous tab, do not need to be repeated here. Text describing the primary site and histology (including behavior and grade) MUST be included here to validate the codes selected above.

21 Section VIII.4: Entering Tumor Data on the Tumor Data Tab - continued Site* Select the organ/tissue in which the primary tumor arose/originated. Only the codes for urinary related sites have been provided in the drop down menu. If the exact site cannot be identified, but it is known to have originated in the urinary tract, select code C68.9 Urinary System, NOS If the exact site cannot be identified, but it is known to have originated in the male genital / genitourinary tract, select code C63.9 Male Genital, NOS Codes ending in.9 are used when there was a single tumor that overlapped the boundaries of two or more sub-sites and the point of origin could not be determined (Bladder, NOS C67.9) or there is not a choice of sub-sites (Prostate C61.9) Dx Confirmation Select the code that describes the best diagnostic method used to confirm the cancer being reported. The coded are listed in priority order. Code 1 has the highest priority. If the presence of cancer is confirmed with multiple diagnostic methods, select the code with the lower numeric value. If the presence of cancer is confirmed with multiple diagnostic methods, select the code with the lower numeric value. Code 1 (positive histology) includes: Tissue specimens from biopsy, frozen section, surgery, autopsy or D&C, aspiration or biopsy of bone marrow. Code 2 (positive cytology) includes: Cytologic examination of cells such as sputum smears, bronchial brushings, bronchial washings, prostatic secretions, breast secretions, gastric fluid, spinal fluid, peritoneal fluid, pleural fluid, urinary sediment, cervical smears and vaginal smears, or from paraffin block specimens from concentrated spinal, pleural, or peritoneal fluid.

22 Section VIII.4: Entering Tumor Data on the Tumor Data Tab - continued Histology* Select the code that best describes the histology of the tumor. Only histologies that commonly arise in urinary related sites have been provided in the drop down menu. Record the histology based on the FINAL DIAGNOSIS (this includes addendums, comments and revised/amended diagnoses) of the pathology report that contained the most representative tumor specimen examined. If there was not a pathology report, use the following priority order to identify which report best represents the histology to be coded. Cytology report Documentation in the record that references pathology or cytology findings Any mention of the type of cancer (histology) in the medical record. If the exact histology is not listed in the menu, select the term that best matches the histology. If that cannot be done, code to 80003, Malignancy NOS Note: It is very important to enter the description of the site and histology EXACTLY as stated in the pathology report (or record). Pay particular attention to the behavior code in the drop down list. The behavior code is the number at the end of each code. Many terms are listed twice, once as in situ (ends with 2) and another as invasive (ends with 3). Select the code with the appropriate behavior code to describe whether the tumor was in situ (/2) or invasive (/3)

23 Section VIII.4: Entering Tumor Data on the Tumor Data Tab - continued Laterality* Tumor Status Tumor Size If the primary site is a bilateral organ, the side in which the tumor originated (laterality) must be specific. The following are the paired organs for urinary related sites only. C62.0 C62.9 Testis C63.0 Epididymis C63.1 Spermatic cord C64.9 Kidney, NOS C65.9 Renal pelvis C66.9 Ureter Use code 0 for all other non-paired organs Use code 4 if the following conditions are met (e.g. bilateral Wilm s tumors): There was a bilateral involvement at time of diagnosis, It contained the same histology, And it is considered a single primary. At the time of the last visit to your office, indicate whether the patient had evidence of this disease or was considered disease free. Record the largest dimension or diameter of the primary tumor. Must be exactly three numbers. Enter leading 0 s to equal three numbers. Record the tumor size in millimeters. Convert centimeters to millimeters by multiplying the dimension by 10. Tumor is 2.5 cm. Record as 025 (2.5 cm = 25 mm) Tumor is 4 cm. Record as 040 (4 cm = 40 mm) Round up or down to the nearest millimeter Tumor is 6.5 millimeters. Record as 007 (round up) Tumor is 2.3 millimeters. Record as 002 (round down) Record 999 if the tumor size is unknown or not stated.

24 Section VIII.4: Entering Tumor Data on the Tumor Data Tab - continued Use free text in the following designated text areas to describe the facts about the stage (extent of disease) of the cancer at the time of diagnosis. These three text areas may not be left blank. This information will be used by the NCCCR staff to code 42 data items related to the stage of the tumor. Be as specific as possible, even if it means repeating information from the previous tab. Include descriptive words such as consistent with, probably, suggests, with features of, abutting, extending to, etc. Enter NONE to indicate there was not information available from the workup to evaluate that particular extent of disease (extension, lymph nodes, or mets). Summarize the extent of the disease using all of the workup performed (clinical and pathologic). This includes the findings from the physical exam, imaging, scopes, lab work, biopsies, surgeries, etc. For these three text areas, the date or place of the procedure does not need to be repeated unless it is needed to clarify the information. Extension* Mets at Dx* Lymph Node involvement* From all of the workup performed, summarize the extent of the primary tumor. Summarize the following: Tumor size Involvement with the primary organ Extension into surrounding tissues. From all of the workup performed, summarize any evidence of metastatic disease present at the time of diagnosis. It is very important to differentiate metastatic disease present at the time of diagnosis and metastatic disease discovered after initial diagnosis and treatment. From all of the workup performed, summarize any evidence of regional lymph node involvement present at the time of diagnosis. Summarize the following: Name of the lymph node chain involved Number of lymph nodes involved Number of lymph nodes examined Any documentation that the lymph nodes were evaluated and were negative.

25 Section VIII.4: Entering Tumor Data on the Tumor Data Tab - continued Use the following date fields to record the start date for each type of treatment received for this tumor. If that particular treatment was not given, leave the date blank and select code 11 as the corresponding date flag. Refer to Section VII.2: General Instruction for Using the Date Entry Screens for more information on how to complete the Date and Date Flag fields. Use free text in the corresponding text area to describe that particular first course of treatment. See the definition of first course treatment below. These text areas may be left blank if that particular treatment was not given. No therapy is a treatment option that occurs if the patient refuses treatment, the family or guardian refuses treatment, the patient dies before treatment starts, or the physician recommends no treatment to be given (patient is too sick, watchful waiting, etc.). If no treatment is given, record the reason for no treatment in any one of the following text areas. Radiation Date, Flag, Text Record the start date for the radiation therapy delivered to the patient as part of the first course of therapy. In the text area, describe as much as is known about the following: Start and end dates Place/facility given Area of body treated Modality (type, energy) Dose (amount of radiation)

26 Section VIII.4: Entering Tumor Data on the Tumor Data Tab - continued Surgery Date, Flag, Text Record the first date caner-directed surgery was performed as part of the first course of therapy. If multiple surgical procedures were performed, record the date of the first surgical procedure. Do not include biopsy dates unless the biopsy removed the entire tumor. In the text area, describe as much as is known about the following: Procedure date Place/facility performed Chemo Date, Flag, Text Hormone Date, Flag, Text Immunotherapy Date, Flag, Text Other Treatment Date, Flag, Text It is important to delineate the specific details for each procedure performed. While biopsies are not included in the Surgery Date, a summary of any biopsies should be included in the Surgery Text. For each of these treatment types, record the first start date for that treatment delivered to the patient as part of the first course of therapy. If multiple drugs were given, record the date the first drug was taken. For each of the treatment types, describe as much as is known about the following: Start and end dates Place/facility given Name of each drug/treatment given Note: Other Treatment includes any treatment that does not qualify as Radiation, Surgery, Chemo, Hormones, or Immunotherapy. Other treatment also includes experimental and non-traditional treatment.

27 Section VIII.4: Entering Tumor Data on the Tumor Data Tab - continued Remarks Required text: This is very important in making sure the best site and histology codes are recorded during final coding by the NCCCR staff. Record the following EXACTLY as stated in the medical record: Primary site, including exact subsite and laterality. Histology, including whether it was invasive or in situ, and the grade (including site specific grading systems). Include descriptive phrases such as consistent with, probably, suggests, with features of, abutting, extending to, etc. In addition, use this area to provide the following information: Record the date of diagnosis and primary site for any other primaries this patient has had in their lifetime, regardless if it is being reported by your office. If the facility for the Referred From or Referred To fields was not an available option in the associated selection boxes, record the name of the facility here. For example, Referred from Any Town Hospital. Use this text area to provide any additional pertinent information about this case.

28 Section VIII.4: Entering Tumor Data on the Tumor Data Tab continued Definition of First Course of Treatment First course of treatment includes all methods of treatment recorded in the treatment plan and administered to the patient at the time of the initial diagnosis and before disease progression or recurrence. A treatment plan describes the type(s) of therapies intended to modify or control the malignancy. The documentation confirming a treatment plan may be found in several different sources; for example, medical or clinic records, consultation reports, and outpatient records. All therapies specified in the physician(s) treatment plan are a part of the first course of treatment if they are actually administered to the patient. An established protocol or accepted management guidelines for the disease can be considered a treatment plan in the absence of other written documentation. If there is no treatment plan, established protocol, or management guidelines, and consultation with a physician advisor is not possible, only record treatment that began within four months of the date of initial diagnosis.

29 Part VIII Entering Information Into Completed

May North Carolina Central Cancer Registry

May North Carolina Central Cancer Registry N o r t h C a r o l i n a C e n t r a l C a n c e r R e g i s t r y Instructions and Reporting Requirements Electronic Reporting for Urology Physician Practices May 2013 North Carolina Central Cancer Registry

More information

Electronic Reporting for Facilities. March 2014

Electronic Reporting for Facilities. March 2014 N o r t h C a r o l i n a C e n t r a l C a n c e r R e g i s t r y Instructions and Reporting Requirements Electronic Reporting for Facilities March 2014 North Carolina Central Cancer Registry State Center

More information

Requirements for Abstracted Text

Requirements for Abstracted Text Slide 1 Requirements for Abstracted Text Principles of Abstracting Lesson 3: Purpose of Text Slide 2 Available Text Fields Place of Diagnosis Immunotherapy Chemotherapy Hormone Therapy Other Therapy Radiation

More information

I.2 CNExT This section was software specific and deleted in 2008.

I.2 CNExT This section was software specific and deleted in 2008. CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES FOR HOSPITALS California Cancer Reporting System Standards, Volume I Changes and Clarifications 8th th Edition Revised May 2008 SECTION

More information

This section allows identifying the facility, this information is important for data quality follow up. Source of Standard. Source of Standard

This section allows identifying the facility, this information is important for data quality follow up. Source of Standard. Source of Standard Data Dictionary Case Administration This section allows identifying the facility, this information is important for data quality follow up Facility Name This identifier is needed to evaluate This data

More information

2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules.

2007 New Data Items. Slide 1. In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules. Slide 1 2007 New Data Items Data Due in: Days In this presentation we will discuss five new data items that were introduced with the 2007 MPH Coding Rules. Slide 2 5 New Data Items Ambiguous Terminology

More information

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines

4/10/2018. SEER EOD and Summary Stage. Overview KCR 2018 SPRING TRAINING. What is SEER EOD? Ambiguous Terminology General Guidelines SEER EOD and Summary Stage KCR 2018 SPRING TRAINING Overview What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets SEER Summary Stage 2018 Site Specific

More information

EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013

EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013 EVERYTHING YOU WANTED TO KNOW ABOUT. Robin Billet, MA, CTR, Head & Neck CTAP Member May 9, 2013 Head and Neck Coding and Staging Head and Neck Coding and Staging Anatomy & Primary Site Sequencing and MPH

More information

Interactive Discussion of Part I CS Coding Instructions: Working the Cases

Interactive Discussion of Part I CS Coding Instructions: Working the Cases Interactive Discussion of Part I CS Coding Instructions: Working the Cases April Fritz, RHIT, CTR Donna M. Gress, RHIT, CTR Jennifer Ruhl, RHIT, CCS, CTR This presentation was supported by the Cooperative

More information

Web Plus Instructions Radiation CCR

Web Plus Instructions Radiation CCR Web Plus Instructions Radiation CCR To begin entering Abstracts through Web Plus, you must first log into https://webplus.njscr.org/webplus/logonen.aspx with credentials that are provided to you once your

More information

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I

CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I CANCER REPORTING IN CALIFORNIA: ABSTRACTING AND CODING PROCEDURES California Cancer Reporting System Standards, Volume I Changes and Clarifications 16 th Edition April 15, 2016 Quick Look- Updates to Volume

More information

Prostate Case Scenario 1

Prostate Case Scenario 1 Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has

More information

11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR

11/3/2016. Outcomes Watching It Grow. What will we discuss? GATRA Annual Conference 2016 Lisa Connor, CTR Outcomes Watching It Grow GATRA Annual Conference 2016 Lisa Connor, CTR The abstract begins after case finding The abstract is in progress The abstract is complete The abstract is revisited and nurtured

More information

The Components of an Abstract. Alfreda Woods, BS, CHES, CTR Program Manager, DCCR DelMarVa-DC Educational Conference October 12, 2018

The Components of an Abstract. Alfreda Woods, BS, CHES, CTR Program Manager, DCCR DelMarVa-DC Educational Conference October 12, 2018 The Components of an Abstract Alfreda Woods, BS, CHES, CTR Program Manager, DCCR DelMarVa-DC Educational Conference October 12, 2018 1 Abstracts Should Tell A Story 2 The Components of an Abstract Who

More information

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on?

MPH Quiz. 1. How many primaries are present based on this pathology report? 2. What rule is this based on? MPH Quiz Case 1 Surgical Pathology from hysterectomy performed July 11, 2007 Final Diagnosis: Uterus, resection: Endometrioid adenocarcinoma, Grade 1 involving most of endometrium, myometrial invasion

More information

5/8/2014. AJCC Stage Introduction and General Rules. Acknowledgements* Introduction. Melissa Pearson, CTR North Carolina Central Cancer Registry

5/8/2014. AJCC Stage Introduction and General Rules. Acknowledgements* Introduction. Melissa Pearson, CTR North Carolina Central Cancer Registry AJCC Stage Introduction and General Rules Linda Mulvihill Public Health Advisor NCRA Annual Meeting May 2014 National Center for Chronic Disease Prevention and Health Promotion Division of Cancer Prevention

More information

APPENDIX I. Free-Standing Radiation Therapy Centers Cancer Case Identification Program

APPENDIX I. Free-Standing Radiation Therapy Centers Cancer Case Identification Program APPENDIX I Free-Standing Radiation Therapy Centers Cancer Case Identification Program I-1 Sending Radiation Therapy data to FCDS Beginning January 1, 2003, all Florida Radiation Therapy Centers must send

More information

MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR

MCR: MANAGEMENT OF 2018 CHANGES. By: Maricarmen Traverso-Ortiz MPH, CGG, CTR MCR: MANAGEMENT OF 2018 CHANGES By: Maricarmen Traverso-Ortiz MPH, CGG, CTR LEARNING OBJECTIVES Discuss a summary of the new changes for 2018 Overview of how the Maryland Cancer Registry is managing and

More information

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Case Scenario 1. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised. Case Scenario 1 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of

More information

Prostate Overview Quiz

Prostate Overview Quiz Prostate Overview Quiz 1. The path report reads: Gleason 3 + 4 = 7. The Gleason s score is a. 3 b. 4 c. 7 d. None of the above 2. The path report reads: Moderately differentiated adenocarcinoma of the

More information

Cancer Registry Abstracting FLORIDA CANCER DATA SYSTEM

Cancer Registry Abstracting FLORIDA CANCER DATA SYSTEM Cancer Registry 1 Learning Objectives 2 Integrate previously learned principles of cancer identification (anatomy, casefinding, site and histology identification principles, staging principles, and treatment

More information

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation *

ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * ACOS Inquiry and Response Selected Inquires CS Tumor Size/Extension Evaluation, CS Lymph Nodes Evaluation, CS Metastasis at Diagnosis Evaluation * CS Tumor Size/Extension Evaluation 24842 12/11/2007: Q:

More information

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy.

1/25/13 Right partial nephrectomy followed by completion right radical nephrectomy. History and Physical Case Scenario 1 45 year old white male presents with complaints of nausea, weight loss, and back pain. A CT of the chest, abdomen and pelvis was done on 12/8/12 that revealed a 12

More information

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised.

Case Scenario. 7/13/12 Anterior floor of mouth biopsy: Infiltrating squamous cell carcinoma, not completely excised. Case Scenario 7/5/12 History A 51 year old white female presents with a sore area on the floor of her mouth. She claims the area has been sore for several months. She is a current smoker and user of alcohol.

More information

Faster Cancer Treatment Indicators: Use cases

Faster Cancer Treatment Indicators: Use cases Faster Cancer Treatment Indicators: Use cases 2014 Date: October 2014 Version: Owner: Status: v01 Ministry of Health Cancer Services Final Citation: Ministry of Health. 2014. Faster Cancer Treatment Indicators:

More information

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) =

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ 2 Primary Site (291) = C711 Date of Diagnosis (283) = Follow-up, Data Quality and Utilization Lesson 8 Page 5: Correcting the Edits Report Instructions: Use the spaces provided to fix the edit by providing the valid value for the incorrect data item. This

More information

Staging for Residents, Nurses, and Multidisciplinary Health Care Team

Staging for Residents, Nurses, and Multidisciplinary Health Care Team Staging for Residents, Nurses, and Multidisciplinary Health Care Team Donna M. Gress, RHIT, CTR Validating science. Improving patient care. Learning Objectives Introduce the concept and history of stage

More information

NAACCR Webinar Series 1

NAACCR Webinar Series 1 NAACCR 2009 2010 Webinar Series Collecting Cancer Data: Kidney 1 Questions Please use the Q&A panel to submit your questions Send questions to All Panelist 2 Fabulous Prizes 3 NAACCR 2009 2010 Webinar

More information

Canadian Cancer Registry Reference Guide For Years

Canadian Cancer Registry Reference Guide For Years Canadian Cancer Registry Reference Guide For Years 2000-2015 Compiled by: Edna Kalu, Zikuan Liu HOW TO OBTAIN MORE INFORMATION For more information about this guide or other services and data available

More information

A Comprehensive Approach to. International Cancer Survival Benchmarking. SurvMark-2

A Comprehensive Approach to. International Cancer Survival Benchmarking. SurvMark-2 A Comprehensive Approach to International Cancer Survival Benchmarking SurvMark-2 Call for Data Data specification June 2016 The deadline for data submission will be 15 September 2016 and it is essential

More information

Interactive Staging Bee

Interactive Staging Bee Interactive Staging Bee ROBIN BILLET, MA, CTR GA/SC REGIONAL CONFERENCE NOVEMBER 6, 2018? Clinical Staging includes any information obtained about the extent of cancer obtained before initiation of treatment

More information

Change Log V1.3- v1.4

Change Log V1.3- v1.4 Change Log V1.3- v1.4 This document shows the changes that were made to the SSDI manual and the Grade manual for the SEER*RSA version 1.4 release on (Date TBD). SSDI Manual Section: General Instructions

More information

Cancer as a Disease. Linda D. Rego, CTR March 2009

Cancer as a Disease. Linda D. Rego, CTR March 2009 Cancer as a Disease Linda D. Rego, CTR March 2009 Historic perspective First records date as early as 2500 B.C. In Egypt recorded on papyrus Outlines pharmacological, mechanical and magical treatments

More information

Lesson 8 Classifications

Lesson 8 Classifications Lesson 8 Classifications Donna M. Gress, RHIT, CTR Validating science. Improving patient care. This presentation was supported by the Cooperative Agreement Number DP13-1310 from The Centers for Disease

More information

CERVIX MEASURE SPECIFICATIONS

CERVIX MEASURE SPECIFICATIONS Cancer Programs Practice Profile Reports (CP 3 R) CERVIX MEASURE SPECIFICATIONS Introduction The Commission on Cancer s (CoC) National Cancer Data Base (NCDB) staff has undertaken an effort to improve

More information

ICD-O CODING Third Edition

ICD-O CODING Third Edition Slide 1 ICD-O CODING Third Edition PART I An introduction to the ICD-O-3 Coding Manual This is part 1 of a 2-part slide presentation. Use the navigation buttons below this panel to advance the slides.

More information

Evaluation of Abstracting: Cancers Diagnosed in MCSS Quality Control Report 2005:2. Elaine N. Collins, M.A., R.H.I.A., C.T.R

Evaluation of Abstracting: Cancers Diagnosed in MCSS Quality Control Report 2005:2. Elaine N. Collins, M.A., R.H.I.A., C.T.R Evaluation of Abstracting: Cancers Diagnosed in 2001 MCSS Quality Control Report 2005:2 Elaine N. Collins, M.A., R.H.I.A., C.T.R Jane E. Braun, M.S., C.T.R John Soler, M.P.H September 2005 Minnesota Department

More information

Chest Neuroendocrine Tumor Registry

Chest Neuroendocrine Tumor Registry Chest Neuroendocrine Tumor Registry User Manual Version 1.0 1 Introduction... 4 1.1 Preface... 4 1.2 How to use this manual... 4 2 Form A... 5 2.1 Patients personal details... 5 2.2 Details from the medical

More information

Brief Update on Cancer Occurrence in East Metro Communities

Brief Update on Cancer Occurrence in East Metro Communities Brief Update on Cancer Occurrence in East Metro Communities FEBRUARY, 2018 Brief Update on Cancer Occurrence in East Metro Communities Minnesota Department of Health Minnesota Cancer Reporting System PO

More information

Obtaining the diagnosis:

Obtaining the diagnosis: CANCER SURGERY Obtaining the diagnosis: Most cancers are first biopsied in order to determine tumor type. Incisional biopsies extract small portions of tumor for microscopic examination. Excisional biopsies

More information

BREAST CANCER IN IDAHO

BREAST CANCER IN IDAHO BREAST CANCER IN IDAHO 1997-2001 1 2 3 4 5 7 6 Non-Hospital Mammography Facilities Idaho Hospitals Health Districts Idaho County Boundaries This PowerPoint presentation was created as a collaborative effort

More information

Rare Urological Cancers Urological Cancers SSCRG

Rare Urological Cancers Urological Cancers SSCRG Rare Urological Cancers Urological Cancers SSCRG Public Health England South West Knowledge & Intelligence Team 1 Introduction Rare urological cancers are defined here as cancer of the penis, testes, ureter

More information

2010 Cancer Data Collection Updates: Standards Volume II, Introduction. What s New for 2010

2010 Cancer Data Collection Updates: Standards Volume II, Introduction. What s New for 2010 2010 Cancer Data Collection Updates: Standards Volume II, Version 12 NAACCR 2009 2010 Webinar Series Introduction What s New for 2010 Record length and record layout New/changed data items Multiple Primary

More information

Patient Identification Quiz

Patient Identification Quiz Patient Identification Quiz 1. A patient presents to your facility for the first time on 1/1/2009. At that time he has a history of lymphoma (9590/3), melanoma (8720/3) and meningioma (9530/0). These three

More information

Recruiting Active; not recruiting Completed Suspended Terminated. The biological sex of the patient. Female Unknown

Recruiting Active; not recruiting Completed Suspended Terminated. The biological sex of the patient. Female Unknown Clinical Data Form Kidney Carcinoma Clinical Trial Sequencing Project Page 1 The Clinical Data Form (CDF) should be completed for every case. This form can be completed at the time the samples are submitted,

More information

A patient with recurrent bladder cancer presents with the following history:

A patient with recurrent bladder cancer presents with the following history: MP/H Quiz A patient with recurrent bladder cancer presents with the following history: 9/23/06 TURB 1/12/07 TURB 4/1/07 TURB 7/12/07 TURB 11/14/07 Non-invasive papillary transitional cell carcinoma from

More information

CS Tumor Size. We re on the Web! Visit us at www2.kumc.edu/kcr

CS Tumor Size. We re on the Web! Visit us at www2.kumc.edu/kcr VOLUME 17 ISSUE 3 July 2013 We re on the Web! Visit us at www2.kumc.edu/kcr July is UV Awareness Month. It is that time of the year again for summer! This is a great opportunity to talk about skin cancer.

More information

Quiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios.

Quiz 1. Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios. Quiz 1 Assign Race 1, Race 2 and Spanish Hispanic Origin to the following scenarios. 1. 62 year old Brazilian female Race 1 Race 2 Spanish/Hispanic Origin 2. 43 year old Asian male born in Japan Race 1

More information

Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary, Eighth Edition. COC Collect. COC Transmit

Standards for Cancer Registries, Volume II: Data Standards and Data Dictionary, Eighth Edition. COC Collect. COC Transmit 10 Record Type R R NAACCR 20 Patient ID Number R R R Reporting Registry 30 Registry Type NAACCR 35 FIN Coding System S NAACCR 37 Reserved 00 40 Registry ID S R R NAACCR 50 NAACCR Record Version R R NAACCR

More information

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS

Exercise 15: CSv2 Data Item Coding Instructions ANSWERS Exercise 15: CSv2 Data Item Coding Instructions ANSWERS CS Tumor Size Tumor size is the diameter of the tumor, not the depth or thickness of the tumor. Chest x-ray shows 3.5 cm mass; the pathology report

More information

Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012

Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012 Q&A Session NAACCR Webinar Series Collecting Cancer Data: Pancreas January 05, 2012 Q: Will sticky notes be transferrable from the previous electronic version of CS to the updated version? A: It is our

More information

NAACR Treatment Webinar Quiz 1

NAACR Treatment Webinar Quiz 1 NAACR Treatment Webinar Quiz 1 1. Which of the following would NOT be considered cancer-directed treatment? a. Hemicolectomy b. Incisional biopsy c. Whole breast radiation d. MRI e. All of the above f.

More information

Exercise. Discharge Summary

Exercise. Discharge Summary Exercise Discharge Summary A 32-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was present

More information

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue

Case Scenario 1. Pathology report Specimen from mediastinoscopy Final Diagnosis : Metastatic small cell carcinoma with residual lymphatic tissue Case Scenario 1 Oncology Consult: Patient is a 51-year-old male with history of T4N3 squamous cell carcinoma of tonsil status post concurrent chemoradiation finished in October two years ago. He was hospitalized

More information

Format Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te

Format Of ICD-O Terms In Numerical List Each topographic and morphologic term appears only once The first listed term in Bold Type is the Preferred Te Florida Cancer Data System International Classification of Diseases for Oncology ICD-O-3 1 Basic Concepts Primary Site/Topography Histology/Morphology Behavior Grade/Immunophenotype 2 ICD-O 3 Structure/Format

More information

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases.

Case Scenario 1. 4/19/13 Bone Scan: No scintigraphic findings to suggest skeletal metastases. Case Scenario 1 3/8/13 H&P 68 YR W/M presents w/elevated PSA. Patient is a non-smoker, current alcohol use. Physical Exam: On digital rectal exam the sphincter tone is normal and there is a 1 cm nodule

More information

Tuberculosis in Chicago 2007

Tuberculosis in Chicago 2007 City of Chicago Communicable Disease Information Department of Public Health Richard M. Daley, Mayor May 2008 Terry Mason, MD, FACS, Commissioner www.cityofchicago.org/health/ West Side Center For Disease

More information

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was

More information

Introduction & Descriptors

Introduction & Descriptors AJCC 8 th Edition Staging Introduction & Descriptors Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving

More information

Non-Gynecologic Cytology Specimen Handling & Collection Instructions

Non-Gynecologic Cytology Specimen Handling & Collection Instructions Page 1 of 6 Non-Gynecologic Cytology Specimen Handling & Collection Instructions Labelling and Requisition Requirements Specimen Container Patients full name ( printed in same format as patients health

More information

Glossary of Terms Primary Urethral Cancer

Glossary of Terms Primary Urethral Cancer Patient Information English Glossary of Terms Primary Urethral Cancer Advanced cancer A tumour that grows into deeper layers of tissue, adjacent organs, or surrounding muscles. Anaesthesia (general, spinal,

More information

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by

AJCC 8 th Edition Staging. Introduction & Descriptors. Learning Objectives. This webinar is sponsored by AJCC 8 th Edition Staging Introduction & Descriptors Donna M. Gress, RHIT, CTR Technical Editor, AJCC Cancer Staging Manual First Author, Chapter 1: Principles of Cancer Staging Validating science. Improving

More information

Collaborative Staging

Collaborative Staging Slide 1 Collaborative Staging Site-Specific Instructions Prostate 1 In this presentation, we are going to take a closer look at the collaborative staging data items for the prostate primary site. Because

More information

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult

Case Scenario 1 Discharge Summary Pathology Report Final Diagnosis: Oncology Consult Case Scenario 1 Discharge Summary A 31-year-old Brazilian male presented with a 6 month history of right-sided scrotal swelling. Backache was present for 2 months and a history of right epididymitis was

More information

Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data,

Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data, Data Quality Analysis of Prostate Cancer Site Specific Factors in Metropolitan Detroit SEER Data, 2004-2012 Jeanne Whitlock, MSLS, CTR Julie George, MS Ron Shore, MPH Fawn D. Vigneau, JD, MPH Metropolitan

More information

CANCER FACTS & FIGURES For African Americans

CANCER FACTS & FIGURES For African Americans CANCER FACTS & FIGURES For African Americans Pennsylvania, 2006 Pennsylvania Cancer Registry Bureau of Health Statistics and Research Contents Data Hightlights...1 Pennsylvania and U.S. Comparison...5

More information

Collaborative Stage. Site-Specific Instructions - LUNG

Collaborative Stage. Site-Specific Instructions - LUNG Slide 1 Collaborative Stage Site-Specific Instructions - LUNG In this presentation, we are going to review the AJCC Cancer Staging criteria for the lung primary site. Slide 2 Reading Assignments As each

More information

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1

Q&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1 Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1

More information

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System

Kyle L. Ziegler, CTR. California Cancer Registry U.C. Davis Health System Kyle L. Ziegler, CTR California Cancer Registry U.C. Davis Health System Overview New Data Items Reportability Clarifications New Coding Rules Grade ICD-O-3 Changes Collaborative Stage v0205 2 New Data

More information

MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES

MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES MEASUREMENT OF EFFECT SOLID TUMOR EXAMPLES Although response is not the primary endpoint of this trial, subjects with measurable disease will be assessed by standard criteria. For the purposes of this

More information

Seventh Edition Staging 2017 Breast

Seventh Edition Staging 2017 Breast Seventh Edition Staging 2017 Breast Donna M. Gress, RHIT, CTR Validating science. Improving patient care. No materials in this presentation may be repurposed in print or online without the express written

More information

AllinaHealthSystems 1

AllinaHealthSystems 1 2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology

More information

Case Scenario 1: Thyroid

Case Scenario 1: Thyroid Case Scenario 1: Thyroid History and Physical Patient is an otherwise healthy 80 year old female with the complaint of a neck mass first noticed two weeks ago. The mass has increased in size and is palpable.

More information

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER

BLADDER PROSTATE PENIS TESTICLES BE YO ND YO UR CA NC ER BLADDER PROSTATE PENIS TESTICLES THE PROSTATE IS A SMALL, WALNUT-SIZED GLAND THAT IS PART OF THE MALE REPRODUCTIVE SYSTEM. IT RESTS BELOW THE BLADDER, IN FRONT OF THE RECTUM AND SURROUNDS PART OF THE URETHRA.

More information

National Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms

National Oncologic PET Registry (NOPR) F-18 Fluoride PET Case Report Forms Form (NOPR) F-18 Fluoride PET Case Report Forms Version Date Patient Information Sheet 06/17/10 (Spanish translation available at: http://www.cancerpetregistry.org/pdf/patient_info_spanish.pdf) Interpreting

More information

Setting the stage for change: upgrading the physician cancer case reporting application in New York

Setting the stage for change: upgrading the physician cancer case reporting application in New York Setting the stage for change: upgrading the physician cancer case reporting application in New York April Austin New York State Cancer Registry (NYSCR) July 12, 2018 June 13, 2018 Aerial view of Thousand

More information

Changes to SEER Data Set for Scope of Regional Lymph Node Surgery

Changes to SEER Data Set for Scope of Regional Lymph Node Surgery Changes to SEER Data Set for 2003 Scope of Regional Lymph Node Surgery Effective 1/1/2003. All primary sites will have the same coding structure for this field None No regional lymph node surgery. No lymph

More information

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules

Multiple Primary and Histology Site Specific Coding Rules URINARY. FLORIDA CANCER DATA SYSTEM MPH Urinary Site Specific Coding Rules Multiple Primary and Histology Site Specific Coding Rules URINARY 1 Prerequisites 2 Completion of Multiple Primary and Histology General Coding Rules 3 There are many ways to view the Multiple l Primary/Histology

More information

2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018

2018 Grade PEGGY ADAMO, RHIT, CTR OCTOBER 11, 2018 1 2018 Grade PEGGY ADAMO, RHIT, CTR ADAMOM@MAIL.NIH.GOV OCTOBER 11, 2018 2 Acknowledgements Donna Hansen, CCR Jennifer Ruhl, NCI SEER Introduction 3 Histologic Type vs. Grade Credit: Dr. Kay Washington

More information

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma

FINE NEEDLE ASPIRATION OF ENLARGED LYMPH NODE: Metastatic squamous cell carcinoma Case Scenario 1 HNP: A 70 year old white male presents with dysphagia. The patient is a current smoker, current user of alcohol and is HPV positive. A CT of the Neck showed mass in the left pyriform sinus.

More information

Curriculum: Goals and Objectives Department of Medicine Harbor-UCLA Medical Center

Curriculum: Goals and Objectives Department of Medicine Harbor-UCLA Medical Center MEDICAL ONCOLOGY AND HEMATOLOGY (R2, R3) A. The PURPOSE of this rotation is to afford medical residents a broad clinical and training experience in the clinical diagnosis and management of common adult

More information

Cancer of Unknown Primary Service

Cancer of Unknown Primary Service Cancer of Unknown Primary Service Dr Maurice Fernando Consultant In Specialist Palliative Care and CUP lead Doncaster and Bassetlaw Hospitals NHS FT Wakefield meeting -14-07-2016 CUP service CUP MDT

More information

NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions

NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions NCDB Vendor Webinar: NCDB Call for Data January 2018 and Upcoming RQRS Revisions American American College College of of Surgeons 2013 Content 2014 Content cannot be be reproduced or or repurposed without

More information

Pathology: Grade 1 infiltrating ductal carcinoma with associated DCIS, Lymphvascular invasion present. ER+, PR+. Her 2/ IHC 1+, negative

Pathology: Grade 1 infiltrating ductal carcinoma with associated DCIS, Lymphvascular invasion present. ER+, PR+. Her 2/ IHC 1+, negative GATRA 2016 Breast Case Demographics Name: Autumn Leaf Sex: F Date of Birth: 3/26/75 SSN: 098765432 Race: African American Marital Status: Single Address: 3615 Burnt Hickory Trail, Helen, GA 37285, White

More information

Confessions of a Data Quality Manager

Confessions of a Data Quality Manager Confessions of a Data Quality Manager FCDS Annual Conference Boca Raton, Florida 7/28/2016 Steven Peace, CTR Outline 20 Data Quality Issues in 45 Minutes Reference Dates & Accession Numbers FCDS Reference

More information

SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING

SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING SEER EOD AND SUMMARY STAGE ABSTRACTORS TRAINING OVERVIEW What is SEER EOD Ambiguous Terminology General Guidelines EOD Primary Tumor EOD Regional Nodes EOD Mets Site Specific Data Items (SSDI) SEER Summary

More information

Fellowship in Cytopathology Department of Pathology. All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India

Fellowship in Cytopathology Department of Pathology. All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India Fellowship in Cytopathology Department of Pathology All India Institute of Medical Sciences (AIIMS) Jodhpur, Rajasthan, India Syllabus for Fellowship in Cytopathology: FNAC Direct, Guided, EUS Exfoliative

More information

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX

QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX QUIZZES WITH ANSWERS FOR COLLECTING CANCER DATA: PHARYNX MP/H Quiz 1. A patient presented with a prior history of squamous cell carcinoma of the base of the tongue. The malignancy was originally diagnosed

More information

PROSTATE CANCER CONTENT CREATED BY. Learn more at

PROSTATE CANCER CONTENT CREATED BY. Learn more at PROSTATE CANCER CONTENT CREATED BY Learn more at www.health.harvard.edu TALK WITH YOUR DOCTOR Table of Contents Ask your doctor about screening and treatment options. WHAT IS PROSTATE CANCER? 4 WATCHFUL

More information

A Time- and Resource-Efficient Method for Annually Auditing All Reporting Hospitals in Your State: the Inpatient & Outpatient Hospital Discharge Files

A Time- and Resource-Efficient Method for Annually Auditing All Reporting Hospitals in Your State: the Inpatient & Outpatient Hospital Discharge Files A Time- and Resource-Efficient Method for Annually Auditing All Reporting Hospitals in Your State: the Inpatient & Outpatient Hospital Discharge Files By Dr. Martin A. Whiteside Director, Office of Cancer

More information

BOUNDARY COUNTY CANCER PROFILE

BOUNDARY COUNTY CANCER PROFILE BOUNDARY COUNTY CANCER PROFILE A fact sheet from the Cancer Data Registry of Idaho, Idaho Hospital Association. Cancer Incidence 2010-2014 Cancer Mortality 2011-2015 BRFSS 2011-2015 CANCER Cancer is a

More information

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ Primary Site (291) = C711 Date of Diagnosis (283) =

1. Laterality, Primary Site E:Lateral & Site conflict Laterality (295) = 0 _ Primary Site (291) = C711 Date of Diagnosis (283) = Follow-up, Data Quality and Utilization Lesson 8 Page 5: Correcting the Edits Report Instructions: Use the spaces provided to fix the edit by providing the valid value for the incorrect data item. This

More information

Providence Medford Medical Center Pathology Department

Providence Medford Medical Center Pathology Department Providence Medford Medical Center Pathology Department Anatomic pathology services including histology, cytology and autopsies are offered through Providence Medford Medical Center Pathology Department.

More information

PBSI-EHR Off the Charts!

PBSI-EHR Off the Charts! PBSI-EHR Off the Charts! Enhancement Release 3.2.1 TABLE OF CONTENTS Description of enhancement change Page Encounter 2 Patient Chart 3 Meds/Allergies/Problems 4 Faxing 4 ICD 10 Posting Overview 5 Master

More information

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site

MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site POLICY: PG0364 ORIGINAL EFFECTIVE: 04/22/16 LAST REVIEW: 07/26/18 MEDICAL POLICY Gene Expression Profiling for Cancers of Unknown Primary Site GUIDELINES This policy does not certify benefits or authorization

More information

Patients who receive image or palpation-guided needle biopsy (core or FNA) for the diagnosis of breast cancer.

Patients who receive image or palpation-guided needle biopsy (core or FNA) for the diagnosis of breast cancer. Description Measure 0221: Needle biopsy to establish diagnosis of cancer precedes surgical excision/resection (Commission on Cancer, American College of Surgeons) Percentage of patients presenting with

More information

Molecular Imaging and Breast Cancer

Molecular Imaging and Breast Cancer Molecular Imaging and Breast Cancer Breast cancer forms in tissues of the breast usually in the ducts, tubes that carry milk to the nipple, and lobules, the glands that make milk. It occurs in both men

More information

QUICK-START GUIDE NCDB Participant Use File (NCDB PUF)

QUICK-START GUIDE NCDB Participant Use File (NCDB PUF) QUICK-START GUIDE 2015 NCDB Participant Use File (NCDB PUF) The data included in this zipped file are provided in a flat text file format, and should be read with software such as SAS, SPSS (PASW), STATA,

More information

2017 Merit-based Incentive Payment System. Avoiding the Penalty

2017 Merit-based Incentive Payment System. Avoiding the Penalty 2017 Merit-based Incentive Payment System Avoiding the Penalty 1 What is the Quality Reporting Program? Quality Payment Program (also known as MACRA) Advanced Alternative Payment Models (APMs) Merit-based

More information